# CJC-1295: The Flight Log of a Long-Acting GHRH Analog > CJC-1295 is a long-acting GHRH analog. Single subcutaneous doses raised GH for 6+ days and IGF-1 for up to 28 days, with a 5.8-8.1-day half-life (Teichman 2006). A cited research digest. A mission-log read of the published record: the human pharmacokinetics that were actually measured, the albumin-conjugation engineering that bought a multi-day half-life, and the points where the data simply stop. ## The CJC-1295 record, read straight CJC-1295 is a synthetic, long-acting analog of growth-hormone-releasing hormone (GHRH). A single subcutaneous dose of 30 or 60 ug/kg raised mean plasma growth hormone 2- to 10-fold for six days or more and IGF-1 for nine to eleven days, with an estimated half-life of 5.8-8.1 days in healthy adults [1]. That is the measured envelope. It is a small envelope — a handful of early human pharmacokinetic studies — and everything past it is engineering rationale, animal data, or open question. The molecule is built on hGRF(1-29), the first 29 residues of human growth-hormone-releasing factor, carrying four amino-acid substitutions (D-Ala at position 2, Gln at 8, Ala at 15, Leu at 27) that block dipeptidylpeptidase-IV cleavage, deamidation, and oxidation [2]. In the DAC variant, a C-terminal linker covalently binds circulating serum albumin, extending the plasma half-life toward that of albumin itself [2]. The no-DAC form — "Modified GRF 1-29" — keeps the four substitutions but lacks the albumin-binding moiety and is short-acting [11]. This site reads that record as a flight log. Each measured datum is logged to its study; each gap is flagged where the data stop. It is editorial commentary on [the human and animal research](/research), not guidance for use. ## What is CJC-1295? CJC-1295 is a synthetic long-acting analog of growth-hormone-releasing hormone (GHRH), built on hGRF(1-29) with four protease-resistant substitutions; the DAC variant adds covalent serum-albumin conjugation for a multi-day half-life [2]. It is not a blend and not a hormone replacement — it is a single peptide secretagogue that prompts the pituitary to release the body's own growth hormone. ## What does CJC-1295 do? It binds the GHRH receptor on anterior-pituitary somatotrophs, stimulating synthesis and pulsatile release of growth hormone, which in turn raises hepatic IGF-1 [3]. The four substitutions plus, in the DAC variant, albumin conjugation hold that stimulation in place for days [2]. Notably, the pulsatile pattern of GH secretion persists despite the sustained signal [3]. ## CJC-1295 as a Research Peptide As a research peptide, CJC-1295 is a lyophilized GHRH analog handled in laboratory contexts, not an approved medicine. It is unapproved for human use anywhere and is sold by research suppliers for laboratory use [1]. The four-substitution backbone gives it protease resistance; the optional DAC moiety gives the long-acting variant its multi-day duration [2]. The CJC-1295 peptide is, in practice, two distinct pharmacokinetic species — the long-acting DAC form and the short-acting no-DAC "Modified GRF 1-29" — routinely conflated in marketing [11]. ## Where CJC-1295 Sits Among GHRH Analogs As a GHRH analog, CJC-1295 belongs to the same class as sermorelin and the FDA-approved tesamorelin — all synthetic versions of the hypothalamic hormone that prompts the pituitary to release growth hormone. A 2025 Nature Reviews Endocrinology review synthesizes the pharmacology of this class, describing receptor signaling and the rationale for long-acting analog design [13]. What separates CJC-1295 within the class is the engineering: the DAC albumin-conjugation that pushes its duration from minutes-to-hours into days [2]. Among GHRH analogs it is the long-acting outlier whose approved-drug program nonetheless did not advance. ## How the mechanism reads on the console The pathway is short and well-mapped. CJC-1295 binds the GHRH receptor — a class B G-protein-coupled receptor on anterior-pituitary somatotrophs — activating Gs/cAMP/PKA signaling that drives GH gene transcription and pulsatile release [3]. Released GH reaches the hepatic GH receptor, triggers JAK2/STAT5 signaling, and raises IGF-1, the downstream hormone that mediates much of GH's anabolic action [1]. Each step is a documented link, which is why the hormone telemetry is the part of this compound's record that reads cleanly. The sustained-stimulation design is the deliberate engineering choice. Native GHRH is destroyed within minutes; the four substitutions block that, and albumin conjugation in the DAC variant holds the signal for days [2]. The result measured in healthy adults was a 2- to 10-fold GH rise sustained for six days or more on a single dose [1] — a long-residence GHRH signal rather than an exogenous GH bolus. ## What this log does not measure The honest readout matters as much as the measured one. There are no large human efficacy trials and no long-term human safety data for CJC-1295 [1]. The ConjuChem Phase 2 program in HIV-associated visceral obesity (NCT00267527) was discontinued, and the long-acting DAC program did not advance [7]. CJC-1295 is unapproved for human use anywhere; the 2024 FDA Pharmacy Compounding Advisory Committee reviewed the GH-secretagogue class and did not recommend it for the 503A compounding bulks list [1]. And it is prohibited at all times in sport under WADA Section S2 [1]. Those flagged lines — not a list of promised benefits — are the rest of the record. --- A flight-log read of the CJC-1295 record — measured telemetry where the studies exist, flagged gaps where they stop, no clinic behind the console and nothing here dispensed or sold.